Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1991009311) METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/009311 International Application No.: PCT/US1990/007239
Publication Date: 27.06.1991 International Filing Date: 07.12.1990
Chapter 2 Demand Filed: 01.07.1991
IPC:
G01N 33/68 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
Applicants:
SENETEK PLC [GB/US]; Six The Pines Court, Suite D St. Louis, MO 63141, US
Inventors:
COPPARD, Nicholas, J.; GB
Agent:
WATT, Phillip, H. ; Room 900 135 South LaSalle Street Chicago, IL 60603, US
Priority Data:
448,11708.12.1989US
Title (EN) METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES
(FR) PROCEDE DE DIAGNOSTIC DE MALADIES NEURODEGENERATIVES
Abstract:
(EN) Provided is a method for diagnosing in a living person an ubiquitin-associated neurodegenerative disease, such as Alzheimer's Disease, Pick's Disease, Parkinson's Disease or progressive supranuclear palsy. The method comprises assaying an aliquot of cerebral spinal fluid from the person for ubiquitin-immunoreactive substances. The invention rests on the surprising discovery that, in living persons with such diseases, but not in living persons without such diseases, there is a significant amount of ubiquitin-immunoreactive substances in the cerebrospinal fluid.
(FR) Procédé de diagnostic, chez une personne vivante, d'une maladie neurodégénérative associée à l'ubiquitine, telle que la maladie d'Alzheimer, la maladie d'Arnold Pick, la maladie de Parkinson, ou la paralysie supranucléaire progressive. Le procédé consiste à analyser un aliquot de liquide céphalo-rachidien prélevé sur la personne afin de déterminer la présence de substances immunoréactives à l'ubiquitine. L'invention repose sur la découverte surprenante que, chez des personnes vivantes atteintes desdites maladies, mais pas chez des personnes vivantes non atteintes desdites maladies, il existe une quantité significative de substances immunoréactives à l'ubiquitine dans le liquide céphalo-rachidien.
Designated States: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, GR, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0504305JPH05503153CA2070812AU1991070616